Earth Science Tech Inc

Earth Science Tech Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.04, indicating minimal leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.85, suggesting potential short-term liquidity constraints. Free cash flow of $267,010 and operating cash flow of $1,206,370 support operational flexibility, though the negative net cash position after subtracting total debt raises some concern.

Profitability metrics show a return on equity of 10.31% and a return on assets of 5.97%, both below the industry median for pharmaceuticals. The company's operating margin of 4.3% (calculated from operating income of $258,490 on revenue of $6,015,870) is also below the sector average, indicating room for improvement in cost control and pricing power.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the pharmaceuticals industry where regulatory and reimbursement environments vary significantly by region.

Looking ahead, the company is projected to see a 41.4% decline in revenue to $35.1 million in the next fiscal year, based on analyst estimates. This represents a significant reversal from the current year's $60.2 million revenue. The decline is likely driven by patent expirations and competitive pressures in key therapeutic areas.

Risk factors include a medium liquidity risk due to the current ratio below 1 and a negative net cash position. The dilution risk is assessed as low, with no near-term pressure expected. However, the company's capital expenditure of -$26,520 suggests underinvestment in growth opportunities, which could impact long-term competitiveness.

Recent filings and transcripts indicate ongoing discussions about pipeline advancements and potential partnerships. The company has not disclosed any material new product launches or regulatory approvals in the latest reporting period, which may contribute to the downward revenue outlook.

Revenue surged 177.1% year-over-year to $33.1 million, demonstrating significant top-line growth momentum for the company.

Net income expanded 300.6% to $3.25 million, indicating strong profitability improvement alongside revenue growth.

Cash conversion of 5.2 is best-in-class compared to the cohort median of 0.95, reflecting high earnings quality.

The stock trades at $0.12, implying 733.3% upside to the consensus price target of $1.00.

Operating margin of 4.3% trails the pharmaceutical cohort median of 5.4%, suggesting lower operational efficiency than peers.

The company faces medium liquidity risk, which could constrain its ability to meet short-term financial obligations.

Debt-to-equity ratio of 0.04 is above the cohort median of 0.18, indicating relatively higher leverage than peers.

Gross profit margin remains thin at approximately 12%, limiting the buffer for operating expense increases.

Revenue $8.4M, +14,1% YoY; Operating income +493,2% YoY.

• ▍Revenue $8.4M, +14,1% YoY
• ▍Operating income +493,2% YoY
• ▍Net income +341,1% YoY
• ▍Free cash flow +288,5% YoY
• ▍Net margin 10.9%

Revenue $9.1M, +6,2% YoY; Operating income −29,8% YoY.

• ▍Revenue $9.1M, +6,2% YoY
• ▍Operating income −29,8% YoY
• ▍Net income +21,1% YoY
• ▍Free cash flow −27,0% YoY
• ▍Net margin 10.7%

Revenue $8.8M, +2,2% YoY; Operating income −77,3% YoY.

• ▍Revenue $8.8M, +2,2% YoY
• ▍Operating income −77,3% YoY
• ▍Net income −56,8% YoY
• ▍Free cash flow −115,1% YoY
• ▍Net margin 5.3%